Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
Outlook Therapeutics (OTLK), which recently secured regulatory approval in the EU and UK for its ophthalmic bevacizumab formulation treating wet AMD, announces its participation in the Guggenheim Healthcare Innovation Conference. CEO Russell Trenary will engage in a fireside chat on November 12, 2024, at 2:30 PM ET in Boston, MA. The management team will also conduct one-on-one meetings with qualified investors attending the conference. A live webcast will be available on the company's website, with the replay accessible for 90 days post-event.
Outlook Therapeutics (OTLK), che recentemente ha ottenuto l'approvazione normativa nell'UE e nel Regno Unito per la sua formulazione oftalmica di bevacizumab per il trattamento della degeneration maculare umida (AMD), annuncia la sua partecipazione alla Guggenheim Healthcare Innovation Conference. Il CEO Russell Trenary parteciperà a una chiacchierata informale il 12 novembre 2024, alle 14:30 ET a Boston, MA. Anche il team di gestione condurrà incontri individuali con investitori qualificati presenti alla conferenza. Una diretta streaming sarà disponibile sul sito web dell'azienda, con la registrazione accessibile per 90 giorni dopo l'evento.
Outlook Therapeutics (OTLK), que recientemente obtuvo la aprobación regulatoria en la UE y el Reino Unido para su formulación oftálmica de bevacizumab para tratar la DMAE húmeda, anuncia su participación en la Guggenheim Healthcare Innovation Conference. El CEO Russell Trenary participará en una charla informal el 12 de noviembre de 2024, a las 2:30 PM ET en Boston, MA. El equipo directivo también llevará a cabo reuniones uno a uno con inversores calificados que asistan a la conferencia. Se ofrecerá una transmisión en vivo en el sitio web de la compañía, y la repetición estará disponible durante 90 días después del evento.
Outlook Therapeutics (OTLK), 최근 EU 및 영국에서 습성 황반변성을 치료하기 위한 안과용 베바시주맙 제제에 대한 규제 승인을 확보한 후, 구겐하임 헬스케어 혁신 컨퍼런스에 참가한다고 발표했습니다. CEO 러셀 트레나리는 2024년 11월 12일 오후 2시 30분 ET에 매사추세츠주 보스턴에서 진행되는 파이어사이드 채팅에 참여할 예정입니다. 경영진 팀은 또한 컨퍼런스에 참석하는 자격을 갖춘 투자자들과 일대일 미팅을 진행할 것입니다. 회사 웹사이트에서 실시간 웹캐스트가 제공되며, 이벤트 후 90일 동안 재생할 수 있습니다.
Outlook Therapeutics (OTLK), qui a récemment obtenu l'approbation réglementaire dans l'UE et au Royaume-Uni pour sa formulation de bévacizumab ophtalmique traitant la DMLA humide, annonce sa participation à la Guggenheim Healthcare Innovation Conference. Le PDG Russell Trenary prendra part à une discussion informelle le 12 novembre 2024, à 14h30 ET à Boston, MA. L'équipe de direction organisera également des réunions individuelles avec des investisseurs qualifiés participant à la conférence. Un webinaire en direct sera disponible sur le site web de l'entreprise, avec un replay accessible pendant 90 jours après l'événement.
Outlook Therapeutics (OTLK), das kürzlich die regulatorische Genehmigung in der EU und im Vereinigten Königreich für seine ophthalmologische Bevazizumab-Formulierung zur Behandlung der feuchten AMD erhalten hat, kündigt seine Teilnahme an der Guggenheim Healthcare Innovation Conference an. CEO Russell Trenary wird am 12. November 2024 um 14:30 Uhr ET in Boston, MA, an einem Fireside-Chat teilnehmen. Das Management-Team wird auch Einzelgespräche mit qualifizierten Investoren führen, die an der Konferenz teilnehmen. Ein Live-Webcast wird auf der Unternehmenswebsite verfügbar sein, mit einer Aufzeichnung, die 90 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET
ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a fireside chat on Tuesday, November 12, 2024 at 2:30 PM ET at the Guggenheim Healthcare Innovation Conference being held in Boston, MA.
In addition to the fireside chat, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the fireside chat will be accessible on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) presenting at the Guggenheim Healthcare Conference?
Where can investors watch Outlook Therapeutics' (OTLK) Guggenheim Conference presentation?
What recent regulatory approvals has Outlook Therapeutics (OTLK) received in 2024?
